Coronary artery bypass surgery perioperative management: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 3: | Line 3: | ||
{{CMG}}; {{AOEIC}} {{VK}} | {{CMG}}; {{AOEIC}} {{VK}} | ||
==[[Coronary artery bypass surgery perioperative management|Perioperative Management]]== | == [[Coronary artery bypass surgery perioperative management|Perioperative Management]] == | ||
[[Coronary artery bypass surgery aspirin and clopidogrel|Aspirin and Clopidogrel]] | [[Coronary artery bypass surgery use of beta-blockers|Beta-Blockers]] | [[Coronary artery bypass surgery use of ACE Inhibitors/ARBs|ACE Inhibitors/ARBs]] | [[Coronary artery bypass surgery management of hyperlipidemia|Management of Hyperlipidemia]] | [[Coronary artery bypass surgery hormonal manipulation|Hormonal manipulation]] | [[Coronary artery bypass surgery management of perioperative infection|Management of Mediastinitis/Perioperative Infection]] | [[Coronary artery bypass surgery percutaneous coronary intervention (PCI) to treat saphenous vein graft failure|Percutaneous Coronary Intervention (PCI) To Treat Saphenous Vein Graft Failure]] | | [[Coronary artery bypass surgery maintaining glucose level|Maintaining Glucose Level]] | [[Coronary artery bypass surgery bleeding/transfusion]] | [[Coronary artery bypass surgery management of dysrhythmias|Management of Dysrhythmias]] | [[Coronary artery bypass surgery smoking cessation|Smoking Cessation]] | [[Coronary artery bypass surgery perioperative management of myocardial dysfunction|Perioperative Management of Myocardial Dysfunction]] | [[Coronary artery bypass surgery perioperative carotid artery noninvasive screening|Perioperative Carotid Artery Noninvasive Screening]] | [[Coronary artery bypass surgery aspirin and clopidogrel|Aspirin and Clopidogrel]] | [[Coronary artery bypass surgery use of beta-blockers|Beta-Blockers]] | [[Coronary artery bypass surgery use of ACE Inhibitors/ARBs|ACE Inhibitors/ARBs]] | [[Coronary artery bypass surgery management of hyperlipidemia|Management of Hyperlipidemia]] | [[Coronary artery bypass surgery hormonal manipulation|Hormonal manipulation]] | [[Coronary artery bypass surgery management of perioperative infection|Management of Mediastinitis/Perioperative Infection]] | [[Coronary artery bypass surgery percutaneous coronary intervention (PCI) to treat saphenous vein graft failure|Percutaneous Coronary Intervention (PCI) To Treat Saphenous Vein Graft Failure]] | | [[Coronary artery bypass surgery maintaining glucose level|Maintaining Glucose Level]] | [[Coronary artery bypass surgery bleeding/transfusion]] | [[Coronary artery bypass surgery management of dysrhythmias|Management of Dysrhythmias]] | [[Coronary artery bypass surgery smoking cessation|Smoking Cessation]] | [[Coronary artery bypass surgery perioperative management of myocardial dysfunction|Perioperative Management of Myocardial Dysfunction]] | [[Coronary artery bypass surgery perioperative carotid artery noninvasive screening|Perioperative Carotid Artery Noninvasive Screening]] | ||
==References== | == General procedular issues for CABG. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization (Please do not edit) == | ||
{| class="wikitable" style="width:80%" | |||
|- | |||
| colspan="1" style="text-align:center; background:LightGreen" | [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen" |<nowiki>"</nowiki>'''1.''' For patients undergoing CABG, establishment of multidisciplinary, evidence based perioperative management programs is recommended to optimize analgesia, minimize opioid exposure, prevent complications and to reduce time to extubation, length of stay, and health care costs''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-NR]])'' <nowiki>"</nowiki> | |||
|} | |||
<ref name="pmid35286170">{{cite journal| author=| title=Correction to: 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. | journal=Circulation | year= 2022 | volume= 145 | issue= 11 | pages= e771 | pmid=35286170 | doi=10.1161/CIR.0000000000001061 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=35286170 }}</ref> | |||
== References == | |||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 12:29, 6 December 2022
|
Coronary Artery Bypass Surgery Microchapters | |
|
Pathophysiology | |
|---|---|
|
Diagnosis | |
|
Treatment | |
|
Perioperative Monitoring | |
|
Surgical Procedure | |
|
Special Scenarios | |
|
Coronary artery bypass surgery perioperative management On the Web | |
|
FDA on Coronary artery bypass surgery perioperative management | |
|
CDC on Coronary artery bypass surgery perioperative management | |
|
Coronary artery bypass surgery perioperative management in the news | |
|
Blogs on Coronary artery bypass surgery perioperative management|- |
|
|
Directions to Hospitals Performing Coronary artery bypass surgery perioperative management | |
|
Risk calculators for Coronary artery bypass surgery perioperative management | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]
Perioperative Management
Aspirin and Clopidogrel | Beta-Blockers | ACE Inhibitors/ARBs | Management of Hyperlipidemia | Hormonal manipulation | Management of Mediastinitis/Perioperative Infection | Percutaneous Coronary Intervention (PCI) To Treat Saphenous Vein Graft Failure | | Maintaining Glucose Level | Coronary artery bypass surgery bleeding/transfusion | Management of Dysrhythmias | Smoking Cessation | Perioperative Management of Myocardial Dysfunction | Perioperative Carotid Artery Noninvasive Screening
General procedular issues for CABG. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization (Please do not edit)
| Class I |
| "1. For patients undergoing CABG, establishment of multidisciplinary, evidence based perioperative management programs is recommended to optimize analgesia, minimize opioid exposure, prevent complications and to reduce time to extubation, length of stay, and health care costs(Level of Evidence: B-NR) " |
References
- ↑ "Correction to: 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 145 (11): e771. 2022. doi:10.1161/CIR.0000000000001061. PMID 35286170 Check
|pmid=value (help).